Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Kadimastem Expands R&D Program to Include Multiple Sclerosis

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). Kadimastem remains on track to submit IND to the FDA before the end of 2022 to begin a multicenter clinical trial of AstroRx® for ALS in 2023 in the U.S. As part of this initiative, the company has signed a service agreement with Hadasit Medical Research Services and Development Ltd. Hadasit is the technology transfer arm of Hadassah Medical Center. It is well known for its partnerships with international companies and research institutions, and its success with groundbreaking medical developments that fill unmet market needs. Under the terms of the agreement, Kadimastem’s astrocyte cells, which comprise AstroRx®, the company’s flagship product for ALS, will be tested for their therapeutic potential for MS using a unique animal model in Professor Tamir Ben-Hur’s laboratory at Hadassah Medical Center. Professor Ben-Hur is the Director of Brain Medicine at Hadassah Ein Kerem Medical Center and a pioneer and opinion leader in the field of clinical research in multiple sclerosis. If successful, the goal is to thereafter plan and conduct a clinical trial of AstroRx® for MS. "We are very excited about the expansion of the range of neurological diseases that astrocyte cells (AstroRx®) could be used to treat. The pre-clinical study that will be conducted at Professor Ben-Hur's laboratory is extraordinary. It’s a first-of-its-kind in the world to treat multiple sclerosis, " said Professor Michel Revel, Israel Prize Winner, Kadimastem Founder and Chief Scientist, and famous for his groundbreaking research that led to the development of the blockbuster drug Rabif for multiple sclerosis. Kadimastem CEO Asaf Shiloni said, “Expanding our R&D activity by conducting the ALS and the MS research in parallel enables us to provide maximum value for patients and investors alike. We are working diligently to move the ALS clinical program ahead. We also hope that AstroRx® will be the answer for the millions of MS patients for whom the usual method of treatment is ineffective. The use of AstroRx® cells, with their various mechanisms of action, may lead to an innovative regenerative treatment for the disease." About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1613 a.shiloni@kadimastem.com Company Website https://www.kadimastem.com/

May 18, 2022 07:00 AM Eastern Daylight Time

Image

Intus Care Announces Technical Assistance and Consulting Services to Support PACE Programs in Achieving Better Participant and Organizational Outcomes

Intus Care

Intus Care, developer of an innovative predictive analytics platform designed for geriatric health, announced today they now offer Technical Assistance and Consulting (TAC) services. These services are aimed at helping PACE programs achieve growth, streamline operations, improve clinical outcomes, reduce unnecessary service utilization costs, and other functional strategies. Intus Care’s team of leading PACE experts will take a hands-on approach alongside PACE programs’ leadership teams and staff to execute and complete project work plans. Intus Care augments improvement projects with organizational data to assist in identifying valid issues and opportunities within a PACE program. “Everyone at Intus Care is personally invested in PACE’s mission of providing quality care to dual Medicare/Medicaid and special needs participants, and we share a vision with PACE to improve clinical outcomes through data and to grow their unique model of care across the country,” said Robbie Felton, chief executive officer, Intus Care. “We are proud to have cultivated a topnotch team comprised of PACE experts that will work hand-in-hand with our PACE partners to help them develop, optimize, and grow their programs.” PACE North in Traverse City, Michigan, has been one of the first programs to utilize Intus Care’s TAC services. Intus Care’s Chief Strategy Officer, Laura Ferrara, has worked closely with PACE North’s leadership team in preparation for their next CMS audit to facilitate new committees, manage interdisciplinary teams, and leverage data to identify the root causes of high utilization events and mitigate proactively. PACE North assisted five (5) participants who were experiencing recurrent falls to decrease falls by 81% between March and April of 2022 based on updated processes. ( See case study ). “By working with Intus Care, we’ve been able to translate data into actions in order to be more proactive when it comes to protecting at-risk participants,” said Michelle Reardon, quality assurance director, PACE North. “Intus Care’s team have provided us a practical, rather than theoretical, roadmap to success which is highly effective towards achieving better health outcomes for our participants.” Intus Care’s TAC services include (but are not limited to): CMS Audit Preparation, Mock Audit Proposals, and Remediation Quality, Compliance, and Utilization Management Program Development Operational Management and Growth The rollout of TAC services will help PACE programs across the country address organizational issues and implement strategies to incorporate the use of patient data into daily operations. Its technology is currently part of PACE plans in seven (7) states and it has recently entered a Letter of Understanding with the National Pace Association to pursue a strategic partnership. Contact us today to discuss what Intus Care can do for your PACE organization. About Intus Care Intus Care synthesizes data to improve care and reduce hospitalizations for some of the most socially vulnerable and clinically complex patients in today’s healthcare system – senior citizens. The company has created a unique data-driven predictive analytics platform designed for organizations such as PACE programs, nursing homes, long-term care facilities, and home care agencies. It easily integrates with existing electronic health records, claims, and financial software to automatically extract and analyze data. By highlighting participant risk and care-focused information, the Intus Care software empowers clinicians, nurses, and other care providers by informing decisions that improve outcomes. Learn more at http://www.intuscare.com/. Contact Details SVM Public Relations Jordan Bouclin and Erika Harris +1 401-490-9700 intuscare@svmpr.com Company Website https://www.intuscare.com/

May 17, 2022 10:00 AM Eastern Daylight Time

BreatheSuite Announces Latest Addition to Board of Directors

BreatheSuite

BreatheSuite Inc., a Canadian connected respiratory health company, today announced that Brad Fluegel officially joined the company’s Board of Directors. In his role, Fluegel will tap into his extensive digital health experience to provide feedback on how to support the company’s growth. “We welcome Brad to the BreatheSuite Board of Directors and look forward to leveraging his knowledge and experience in digital health as we continue to expand the BreatheSuite program,” said Brett Vokey, CEO of BreatheSuite. “We are excited to draw upon his background in commercial healthcare as we continue to work toward improving the lives of respiratory patients worldwide. Brad has exactly the experience we need to navigate the digital health ecosystem.” Before working as an advisor to healthcare organizations, entrepreneurs, and other participants in healthcare, Fluegel was most recently the senior vice president and chief healthcare commercial market development officer for Walgreen Co. based in Deerfield, Ill. He was responsible for all commercial healthcare activities, including sales and contracting, biopharma relationships, retail clinics, clinical affairs, new service development and market planning. Previously, he was chief strategy and business development officer for Walgreens, responsible for corporate strategy and business development. Prior to joining Walgreens, Fluegel served as executive in residence at Health Evolution Partners. Before that he was executive vice president and chief strategy and external affairs officer of Wellpoint (now Anthem), among the nation’s largest health benefits companies. While at Wellpoint, Fluegel was responsible for long-term strategic planning, government affairs, corporate communications including public relations, corporate marketing, corporate development, international expansion, innovation and new business ventures. Fluegel was senior vice president of national accounts and vice president, enterprise strategy at Aetna, Inc. In this role, he led the national accounts business and was responsible for developing and executing on strategies that expanded Aetna’s position as a leader in the large employer market. “I’m excited to join BreatheSuite, as digital healthcare has always been a passion of mine because of its ability to improve people’s lives,” said Fluegel. “I look forward to using my experience to help BreatheSuite achieve its mission to provide better, more transparent care for all people with asthma or COPD.” Fluegel is well versed in the complexities of business and healthcare and is also a lecturer at the University of Pennsylvania’s Wharton School of Business. He earned a master’s degree in public policy from Harvard University’s Kennedy School of Government and a Bachelor of Arts in business administration from the University of Washington. He serves on the Board of Directors of MJHS Health System in New York City, Performant Financial Corporation and Premera Blue Cross, among others. He was also on the board of Fitbit before its sale to Google in early 2021. Fluegel’s appointment to BreatheSuite’s Board of Directors comes on the heels of BreatheSuite’s Chief Scientific Officer, Dr. Meshari F. Alwashmi, joining the Forbes Technology Council. The company also recently announced that it secured a spot on the inaugural Canadian Business New Innovators List. About BreatheSuite BreatheSuite is a Canadian connected health company empowering people with chronic respiratory conditions live longer, healthier lives. The BreatheSuite program incorporates a smart inhaler sensor designed to track and train proper inhaler usage, a BreatheSuite App to gamify getting Asthma & COPD under control, as well as health coaches to support patients wherever they are on their journey. BreatheSuite works with leading partners across North America to deliver better care to people with chronic respiratory conditions. For more information visit www.breathesuite.com or contact info@BreatheSuite.com. Follow us on Twitter, and LinkedIn Contact Details SVM Public Relations Erin O’Brien +1 401-490-9700 erin.obrien@svmpr.com Company Website https://www.breathesuite.com/

May 17, 2022 10:00 AM Eastern Daylight Time

Underline Science Closes Pre-Series A Round To Further Advance Scholarly Research With The Growth Of The Digital Video Library

Underline Science Inc

Most industries have progressed from paper to all forms of content; how is it that one of our most essential industries, science, is staying behind. This is something Underline's founder doesn't understand, and therefore he will change it with the launch of the Underline Digital Video Library (DVL). With a considerable track record, this multi-accomplished founder is now taking on the big publishers in a way that hasn't been seen before as a premier aggregator of streaming scientific conference lecture video content. Together with his team of industry leaders, Underline is aiming to transcend the industry into the 21st century. The mission of Underline is to improve researchers' access to quality scientific conference lecture video content. Historically, if you did not attend a scientific conference, you would miss out on all of the conference's lectures. Underline's DVL contains 26,000+ videos (Health Sciences, Life Sciences, Engineering, Technology, Social Sciences, and Humanities). The video content from the world's prestigious scientific societies and universities, like IEEE, Endocrine, AIP, lecturers from MIT, Harvard, Facebook, Google, etc. Each video is complete with abstract, English transcription, bio, picture of the author, and most importantly, a DOI (digital object identifier), which ensures that the video can be searched and discovered. Today, the company announced that it had raised a $2.5 million Pre-Series A round of funding, led by South Central Ventures and the Dutch Founders Fund. As a result, Mr. Jure Mikuz (South Central Ventures) and Mr. Laurens Groenendijk (Dutch Founders Fund) will join the Underline Board of Directors. "With this new round of funding, we'll be able to enhance the Underline DVL features and content greatly. Further to grow the team and expand our go-to-market strategy," Underline CEO and founder Alex Lazinica said in a press release. "We are looking forward to increasing our penetration into the library, government and corporate, institutional subscription market." South Central Ventures, who led the round, Managing Partner Jure Mikuz, said, “Underline’s mission resonates with us very well as they are addressing a global opportunity of creating a library of global scientific video content. I believe they will be successful by facilitating their excellent execution skills and deep industry knowledge. We are very excited to join Underline on this journey.” Founding Partner Laurens Groenendijk of The Dutch Founders Fund states, " We believe that if Underline Science manages to tap into the apparent possible network effects, it can quickly grow to be the dominant player in science content aggregation. We at Dutch Founders hope to see “underlining become a verb”. If anyone is going to do it, We know a seasoned entrepreneur like Alex is. “ Underline's business model is an annual subscription fee for unlimited access to the entire Digital Video Library for the subscribing institution's community. About Underline Science Underline is the premier virtual conference platform for events in science, medicine, academia, and other professional fields. Underline’s mission is to capture and disseminate scientific knowledge through video, making it globally accessible by enriching and preserving both virtual and hybrid conference content. Underline’s groundbreaking scientific Digital Video Library is providing new opportunities to access and expand the scientific record and accelerate scientific discovery. For more information, visit the Underline website and follow Underline on Twitter. About South Central Ventures South Central Ventures is a VC investor with the longest presence in the Balkans. Operating out of four offices – Ljubljana, Zagreb, Belgrade and Skopje – the team has invested in about 40 early stage tech companies and has been an integral part of the local start up communities. With a strong base of international investors, South Central Ventures is a go-to investor for regional tech companies competing in global markets. SCV’s portfolio companies include Cognism, Celtra, Agrivi, Orgnostic and AdScanner, among others. About Dutch Founders Fund DutchFounders is an early-stage venture capital fund from Amsterdam, started by a group of successful Dutch entrepreneurs like Laurens Groenendijk (Just Eat, Treatwell, Miinto, Hiber), Patrick Kerssemakers (fonQ), Bas Beerens (WeTransfer), Hidde Hoogcarspel (Spacebuzz) and Remco van Zanten ( Booking, Zalando, Vinted and BCG). The fund specialises in marketplaces and companies with strong network effects. Since its launch in 2018, the fund has successfully invested in 16 companies. This includes: YourCampus, Shypple, Vintage Cash Cow, Lumaly, Blanco, Nostics, Reveall, Veylinx, Wonderkind, Voicebooking, Fleks, Minimum, Caya, Winc Academy, Buildstream and Tracedock (exited to CM.com). The total fund has almost €100 million assets under management. DutchFounders is a committed partner of Techleap’s Fundright initiative. ### Contact Details Underline Science, Inc. Darrell W Gunter +1 973-454-3475 darrell@underline.io Company Website https://www.underline.io/

May 17, 2022 09:30 AM Eastern Daylight Time

AppYea expands its SleepX patent commercialization portfolio with a non-diluting agreement.

Appyea

AppYea (OTC: APYP) announced that its subsidiary SleepX, which focuses on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring – has signed new commercialization agreement for two additional patents by Ben-Gurion University. The new patented technology enables the innovative detection of sleep apnea and hypopnea through speech analysis using only a smartphone and with no physical contact. This is compared to traditional technologies that use physical sensors to detect apnea in overnight sleep labs. "In recent years we see a growing number of major players taking development efforts in the field of sleep monitoring and sleep apnea”, said Boris (Bary) Molchadsky, chairman & CEO of AppYea. “We are developing our own products that cater to this market while increasing our patent portfolio and examining synergistic technologies as part of our strategy to become a leading player in the sleep health market while also offering licensing agreements for leading smartphone manufacturers.” SleepX is a research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. SleepX focuses its activities on the development and commercialization of its flagship product SleepX PRO solution which is designed to diagnose sleep apnea using only a smartphone and with no physical contact. The company recently announced that it has applied to the Helsinki Committee for approval to begin its planned clinical trial on the SleepX PRO application. This trial is intended to take place at a hospital sleep lab as the first step toward applying for an FDA approval under the first-of-its-kind medical device category for “contactless detection of sleep apnea to be performed through the Artificial Intelligence (AI) analysis of breathing during sleep”. As far as SleepX is aware, the global sleep apnea devices market size is valued at USD 3.7 billion as of 2020 with a 6.2% CAGR, reaching USD 6.1 billion by 2028, according to Grand View Research’s report. Safe Harbor and Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to our ability to raise capital needed to develop and market our products, the effectiveness of the Registration Statement, our ability to manage the business post acquisition, economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission. Contact Details Asaf Porat +1 800-674-3561 info@appyea.com Company Website http://www.appyea.com

May 16, 2022 07:00 AM Eastern Daylight Time

Funding update: Marquee tech founders and investors join Ultrahuman’s Series A

Ultrahuman

Several prolific tech investors and founders have come together to invest in Ultrahuman, a leading metabolic fitness platform that uses glucose biomarkers to help people optimize their lifestyle. Balaji Srinivasan (ex-Coinbase), Nithin Kamath (founder of Zerodha via Rainmatter) and Preethi Kasireddy (ex-a16z) along with several others have invested in Ultrahuman, the world’s most advanced metabolic fitness platform, in an undisclosed funding amount which will be in addition to their recent series A round. Others influential leaders include Groww founders (Harsh Jain, Lalit Keshre, Neeraj Singh and Ishan Bansal), Razorpay founder, Harshil Mathur and RazorpayX GM - Shashank Mehta, Akshay BD (founding team Uber India) and Tanmay Bhat (celebrity content creator and investor) as they support Ultrahuman, a metabolic fitness platform that helps people optimize their metabolism via real-time biomarkers like glucose in combination with HRV, sleep and activity insights. The metabolic health crisis is unarguably one of the largest healthcare crises that exist today. Over a billion people in the world suffer from a metabolic health disorder which contributes to almost 85% of all chronic diseases in the world. By helping people understand how food and exercise affect their metabolic health, people would be able to make informed choices about what they eat and their activity levels. The approach is a geography/diet agnostic way to help people eat and exercise better. Measuring a powerful biomarker like glucose can reveal so much about how a particular food item affects the user’s metabolic health by measuring the glucose response. This response is unique to an individual and it depends on various factors like their gut microbiome, stress levels, time of the day, food ingredient quality, etc. Ultrahuman launched with Ultrahuman M1 - a metabolic health tracking platform that provides intelligent nudges based on glucose biomarkers. This helps people optimize their exercise, sleep and nutrition based on deep insights from the platform. The M1 tracks the wearer’s metabolism as they go about their day using a continuous glucose monitoring device. It triggers timely personalized nudges to the user such as alerts to high glucose variability events leading to oxidative stress and suggestions to optimize it via lifestyle interventions. Nithin Kamath, founder of Zerodha, added: “A big part of living healthier is tracking your diet and eating right, but the problem is doing this accurately is tricky. The approach that Ultrahuman is taking to tackle this problem of improving metabolic fitness by using biomarkers is really interesting. We're excited to join Mohit and Vatsal on their journey.” Ultrahuman has raised over $25M to date. Existing investors include Alpha Wave, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund, and a range of other angel investors including Tiger Global’s Scott Schleifer. “We’re super excited to welcome some of the world’s foremost founders, investors and biohackers to join our Series A round. The most inspiring aspect of this investment is that most of them are long term users of the platform as well and that strengthens our mission holistically”. said Mohit Kumar, Founder and CEO, Ultrahuman. Ultrahuman was started by Mohit Kumar and Vatsal Singhal who were also co-founders at Runnr which later merged with India’s largest food delivery service Zomato. Mohit is an avid cyclist, biohacker and Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross-fit enthusiast and a biohacker. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai in Thailand). During his training, he observed athletes train smartly via the usage of data, recovery tools and protocols. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. By using glucose and other biomarkers, Ultrahuman is helping people improve their energy levels, lose fat and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://ultrahuman.com/

May 12, 2022 06:30 AM Eastern Daylight Time

Image

CoorsTek Recognized as a US Best Managed Company

CoorsTek

CoorsTek is proud to announce it has been selected as a 2022 US Best Managed Company. Sponsored by Deloitte Private and The Wall Street Journal, the program recognizes outstanding U.S. private companies and the achievements of their management teams. The 2022 designees are U.S. private companies that have demonstrated excellence in strategic planning and execution, a commitment to their people and fostering a dynamic, resilient culture, as well as strong financials. This year’s designees continued to propel their businesses forward by prioritizing purpose, investing in their workforces, and demonstrating their commitment to diversity, equity and inclusion. “We are honored to be recognized as a best managed company again this year,” said Jonathan Coors, CEO of CoorsTek. “This award is a tribute to the dedication and resiliency of our CoorsTek team members across the globe over the past several years. It also speaks to the strong values that guide our daily activities and actions, and our focus on delivering essential products and services to the marketplace.” Applicants are evaluated and selected by a panel of external judges focused on assessing hallmarks of excellence in four key areas: strategy, ability to execute, corporate culture and governance/financial performance. They join a global ecosystem of honorees from more than 40 countries recognized by the Best Managed Companies program. About The Best Managed Companies Program The Best Managed Companies program is a mark of excellence for private companies. U.S. designees have revenues of at least $250 million. Hundreds of private companies around the world have competed for this designation in their respective countries through a rigorous and independent process that evaluates four key criteria in their management skills and practices — strategy, execution, culture and governance/financials. U.S. program sponsors are Deloitte Private and The Wall Street Journal. For more information, visit www.usbestmanagedcompanies.com. Please see www.deloitte.com/us/about for a detailed description of our legal structure. About CoorsTek Founded in 1910 and headquartered in Golden, Colorado, CoorsTek is a fifth-generation, family owned and operated global manufacturer of engineered ceramics. By utilizing over half of the world’s known elements in our material formulations, we deliver unique solutions to our diverse customer base by leveraging ceramic properties. With more than 30 facilities across three continents, five million square feet in manufacturing space, and more than 6,000 team members, we are the partner of choice in engineered ceramics. CoorsTek makes the world measurably better by providing customers with amazing solutions, serving customers in numerous industries including semiconductor, aerospace, automotive, medical, energy and many others around the world. For more information about the company and its products please visit our website at www.coorstek.com. Contact Details CoorsTek Nancy Fullerton +1 517-304-4695 nfullerton@coorstek.com Company Website https://www.coorstek.com

May 11, 2022 03:52 PM Eastern Daylight Time

Shatterproof Statement Regarding the Just Released 2021 CDC Overdose Numbers

Shatterproof

In response to the newly-reported number of overdose deaths in the country, and on the heels of the first-ever National Fentanyl Awareness Day, Shatterproof, a national nonprofit dedicated to reversing the addiction crisis in the United States, announced that they will be addressing the alarming rates at which fentanyl is killing Americans through several targeted policy initiatives. According to the CDC, more than 107,000 people died of an overdose in the year 2021—more than twice the number of U.S. traffic fatalities or gun-violence deaths during that period. Approximately 66 percent of these deaths involved synthetic opioids such as fentanyl and according to the CDC overdose deaths are the leading cause of death for people 18 to 45. The primary driver of the opioid epidemic today is illicit fentanyl, a synthetic opioid that is up to 50 times more potent than heroin. A recent Stanford-Lancet Commission Report warned that, without radical change, the U.S. opioid ten-year death toll could reach to 1.2 million by 2029. The Commission recommended bold changes to address this enormous challenge. The issue is further complicated by the fact that many users are not seeking fentanyl, rather it is laced into heroin, stimulants (cocaine and methamphetamines), and counterfeit pills of brand-named drugs like Oxycontin, Xanax and Adderall, unbeknownst to the user, driving overdoses. This is a multi-dimensional problem: a national security, law enforcement and public health challenge that requires a multi-dimensional solution spanning foreign policy, homeland security, and public health, while developing a deeper understanding of demand for the substances. To address this urgent public health crisis, Shatterproof has developed a national strategy to enact policies that can reverse the alarming trend in deaths from fentanyl. These policies include: Ensuring real-time overdose monitoring through data collection and reporting Ensuring multichannel, broadbased fentanyl-specific education programs Significantly expanding access to and use of naloxone Siginficantly expanding stigma-reduction programs related to those with a substance use disorder Provide law enforcement with necessary tools to stop fentanyl trafficking Integrating evidence-based prevention programming for substance use with other community-based programming for children, and ensuring adequate funding for prevention programs. Testing viability of fentanyl test strips as an intervention by changing state drug paraphernalia laws, as needed, to make them available “It is beyond time that we addressed the scourge that fentanyl has brought to our communities. Fentanyl’s silent and sinister prevalence is reversing otherwise positive trends in treatment quality and addiction stigma reduction. We must reduce the supply of fentanyl and the demand for its effects as logical and urgent next steps in our efforts to save lives, said Gary Mendell, Shatterproof Founder and CEO.” About Shatterproof: Shatterproof is a national nonprofit organization dedicated to reversing the addiction crisis in the United States. Shatterproof harnesses the models of business, the rigor of science and the power of a national movement to create change and save lives through three pillars of work: revolutionizing the addiction treatment system, breaking down addiction-related stigmas and supporting and empowering our communities. To learn more visit www.Shatterproof.org. Contact Details Holly Jespersen +1 646-334-1024 hjespersen@shatterproof.org Company Website https://www.shatterproof.org/

May 11, 2022 10:19 AM Eastern Daylight Time

April 23 has been declared the World Infant, Child and Adolescent Mental Health Day (WICAMHD) by the world’s leading psychiatric organizations for child and adolescence

IACAPAP

SINGAPORE - Media OutReach - 11 May 2022 - Research has shown that most mental disorders develop in childhood and adolescence (before the age of 25), and one-quarter of number of years lost to disability or illness for mental and substance use disorders occur in youths. Recognising the urgency to address this burgeoning issue and to galvanise the global community to take ownership and action, the International Association for Child and Adolescent Psychiatry and Allied Professions ( IACAPAP ), International Society for Adolescent Psychiatry and Psychology ( ISAPP ), World Association for Infant Mental Health ( WAIMH ), and World Psychiatric Association Child and Adolescent Psychiatry ( WPA-CAP ) have jointly declared April 23 as the World Infant, Child and Adolescent Mental Health Day (WICAMHD) with a launch event on that day. Children and adolescents form one third of the world's population. Childhood and adolescence are foundational years and ideally a period of growth, learning and carefree exploration. However, many around the world are inflicted by trauma and crises – adverse experiences which research has demonstrated to impact lifelong mental and physical health. Research has also shown that most mental disorders develop in childhood and adolescence (before the age of 25), and one-quarter of disability-adjusted life years for mental and substance use disorders occur in youths. Adverse Childhood Experiences (ACEs) are also contributing factors in the development of mental disorders in adult years. The indirect and compounding effects of this is a ballooning economic burden on societies, especially in the areas of healthcare utilisation and productivity loss. Below are excerpts from speakers at the Launch: Associate Professor Daniel Fung, President of the IACAPAP said, “Studies of adults with both mental and physical illnesses have also shown that adverse childhood experiences can have long lasting effects later in life. The emphasis by most governments has always been on adults in both financial budgeting as well as policy development. We hope to change this with the World Infant Child and Adolescent Mental Health Day, by relooking our priorities and having the right reasons for planning our future. If there is no health without mental health, then the key to health and well-being of people and nations lies with our young, and we should take early steps to protect their mental health.” Prof Campbell Paul, President for WAIMH said, “Early intervention means intervening early in childhood and before mental health problems become established when it is more difficult to help the child or young person resume a healthy social and emotional developmental trajectory. Around the world mental health services for infants, children and adolescents are patchy and sparse with many countries and communities having literally no access to child mental health services,” Prof Norbert Skokauskas, Chair for WPA-CAP said, “We are aware of the current unmet needs in global child and adolescent mental health and it’s critical for us to call for an integrated approach with a clear vision for change, political support and funding to implement the vision, and trained healthcare workforce to implement the change in clinical practice,”. Prof Mario Speranza, President of the ISAPP said, “Supporting adolescents’ mental health is not just a duty toward a significant part of the population. It may be useful to remind ourselves that children and adolescents represent over a quarter of the world population. It’s much more a question of investing in the most promising elements of our society. Raise the awareness of the specific needs of children and adolescents and supporting their mental health means investing in our very own future. This is the reason for celebrating the World Infant, Child and Adolescent Mental Health Day,” The designation of Apr 23 as WICAMHD draws recognition of the importance of infant, child and adolescent mental health; and encourages stakeholders to advocate for the promotion of mental health and prevention of mental illness in the young by: Improving global public awareness about infant, child and adolescent mental health. Creating literacy and competencies in the promotion of infant, child and adolescent mental health as well as reducing the stigma of mental disorders in these populations. Improving diagnosis, treatment, and prevention of infant, child and adolescent mental disorders through international cooperation and understanding. Reaching out to countries with scarce resources to develop infant, child and adolescent mental health professionals. The prevalence of mental disorders continues to rise in the young and is higher than in older-age groups. An improved understanding of this, as well as better awareness among communities and helping professionals cannot be underestimated. A recording of the launch event can be viewed at https://www.youtube.com/watch?v=jgOV4WR0m7I ABOUT THE ORGANIZATIONS INTERNATIONAL ASSOCIATION FOR CHILD AND ADOLESCENT PSYCHIATRY AND ALLIED PROFESSIONS (IACAPAP) The International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) mission is to advocate for the promotion of the mental health and development of children and adolescents through policy, practice and research. The mission of IACAPAP is to promote child and adolescent psychiatry and the mental health and development of children and adolescents through policy, practice, training and research. For more information, visit: https://iacapap.org/ INTERNATIONAL SOCIETY OF ADOLESCENT PSYCHIATRY AND PSYCHOLOGY (ISAPP) International Society for Adolescent Psychiatry and Psychology (ISAPP) is an organization established to work for the mental health of adolescents, and it is comprised of individual members devoted to working with adolescents, either in the field of child psychiatry and psychology or adult psychiatry and psychology. The International Society for Adolescent Psychiatry and Psychology's (ISAPP) mission is to increase public and professional awareness about the mental health and development of adolescents all around the world. For more information, visit: http://www.isapp.org/ WORLD ASSOCIATION FOR INFANT MENTAL HEALTH (WAIMH) The World Association for Infant Mental Health (WAIMH) is a not-for-profit organization for scientific and educational professionals. WAIMH's central aim is to promote the mental wellbeing and healthy development of infants throughout the world, taking into account cultural, regional, and environmental variations and generating and disseminating scientific knowledge. WAIMH's mission promotes education, research, and study of the effects of mental, emotional and social development during infancy on later normal and psychopathological development through international and interdisciplinary cooperation, publications, affiliate associations, and through regional and biennial congresses devoted to scientific, educational, and clinical work with infants and their caregivers. For more information, visit: https://waimh.org/ WORLD PSYCHIATRIC ASSOCIATION CHILD AND ADOLESCENT PSYCHIATRY SECTION (WPA-CAP) The World Psychiatric Association Child and Adolescent Psychiatry (WPA-CAP) section supports the overall mission and goals of the WPA in: • Working with its members and partners around the world to promote child and adolescent mental health and to encourage the highest possible standards of clinical practice and ethical behaviour in child and adolescent psychiatry. • Contributing to education programs and research, meetings, and publications to increase knowledge about child and adolescent mental disorders and skills in addressing them. • Disseminating knowledge about evidence-based therapy and values-based practice in child and adolescent psychiatry. • Being a voice for the dignity and human rights of young patients and their families• Upholding the rights of the child and adolescent psychiatrists where they may be challenged. For more information, visit: https://www.wpanet.org/child-adolescent-psychiatry #IACAPAP Contact Details International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) Ms Sue Wong info@iacapap.org

May 11, 2022 09:00 AM Eastern Daylight Time

1 ... 217 218 219 220 221 ... 299